Sodium-glucose co-transporter 2 inhibitors beyond diabetes
Australian Prescriber, 2022 Sodium-glucose co-transporter 2 (SGLT2) inhibitors lower blood glucose by reducing the reabsorption of glucose in the kidney. They are a second-line therapy for type 2 diabetes.
Atherton, John J +2 more
core +6 more sources
Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of anti-diabetic agents [PDF]
Drugs in Context, 2014 Although several treatment options are available to reduce hyperglycemia, only about half of individuals with diagnosed diabetes mellitus (DM) achieve recommended glycemic targets.
Eva M Vivian
doaj +2 more sources
Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review [PDF]
Cardiovascular Diabetology, 2023 Sodium-glucose co-transporter-2 inhibitors are used in the treatment of diabetes but are also emerging as cardioprotective agents in heart diseases even in the absence of type 2 diabetes.
Julia Hoehlschen +3 more
doaj +3 more sources
Sodium-glucose co-transporter 2 (SGLT2) inhibitors [PDF]
, 2020 Type 2 diabetes mellitus is a progressive metabolic disorder. Marked hyperglycaemia leads to serious vascular complications. Hence, addressing this modifiable risk factor is of paramount importance.
Gruppetta, Mark +3 more
core +4 more sources
Sodium glucose co-transporter 2 inhibitors in patients with resistant hypertension: a case study [PDF]
JRSM Open, 2016 Sodium glucose co-transporter 2 inhibitors lower blood pressure by osmotic diuresis and can be considered in diabetic patients with resistant hypertension.
Amira Obeid +3 more
doaj +2 more sources
Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary
Frontiers in Cardiovascular Medicine, 2022 A new therapeutic class of oral agents firstly used for the treatment of type 2 diabetes mellitus is represented by gliflozines or sodium-glucose co-transporter 2 (SGLT2) inhibitors.
Annamaria Mascolo +17 more
doaj +3 more sources
Efficacy of sodium-glucose co-transporter-2 inhibitors in patients with heart failure [PDF]
Российский кардиологический журнал, 2021 The article analyzes the new results of randomized clinical trials on the use of sodium-glucose co-transporter-2 inhibitors in patients with cardiovascular diseases, heart failure with and without type 2 diabetes.
E. V. Kovalenko +3 more
doaj +2 more sources
Editorial: Sodium Glucose Co-Transporter 2 Inhibitors and Kidney Function
Frontiers in Pharmacology, 2022 Daniel H. Van Raalte +1 more
doaj +3 more sources
Sodium glucose co-transporter 2 inhibitors in heart failure therapy
Türk Kardiyoloji Derneği Arşivi, 2020 Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) are a new class of drugs for patients with type 2 diabetes (T2DM) which inhibit urinary glucose reabsorption in the proximal tubule of the nephron and result in glucosuria, natriuresis and diuresis.
Yüksel Çavuşoğlu +10 more
doaj +5 more sources
Sodium Glucose Co-transporter 2 Inhibitors and Heart Failure
The American Journal of Cardiology, 2019 Sodium-glucose co-transporter 2 (SGLT2) receptors are primarily located in the proximal convoluted tubule of the nephron. These receptors are responsible for almost 90% to 95% of tubular reabsorption of the glucose in the nephron.
Gupta, Manasvi +8 more
core +6 more sources